POVIZTRA
As listed in the register: POVIZTRA
2.4 mg · solution
- Prescription only
- Digestion, stomach, diabetes and nutrition
- Active substance
- Semaglutide
- Made by
- Novo Nordisk Canada Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Ozempic). It describes the substance, not this exact product.
Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1.
Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.
Approximately 3% of the dose is excreted in the urine as intact semaglutide.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-07-30
Safety of the active substance
From the US prescribing label for the same active substance (Ozempic). It describes the substance, not this exact product.
WARNING: RISK OF THYROID C-CELL TUMORS.
- OZEMPIC is contraindicated in patients with:.
- A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions ( 5.1 )]..
- A serious hypersensitivity reaction to semaglutide or to any of the excipients in OZEMPIC.
- Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with OZEMPIC [see Warnings and Precautions ( 5.8 )]..
The most common adverse reactions reported in ≥5% of patients treated with OZEMPIC are: nausea, vomiting, diarrhea, abdominal pain and constipation.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Novo Nordisk Canada Inc |
|---|---|
| Active substance | Semaglutide |
| Used in | Digestion, stomach, diabetes and nutrition |
| Strength | 2.4 mg |
| Form | solution |
| Classification | A10BJ06 · Digestion, stomach, diabetes and nutrition |
| Route | subcutaneous |
| Dispensing (as stated by the register) | PRESCRIPTION · SCHEDULE D |
| Status | Approved |
| Marketed | No — authorised but not currently marketed, according to the register |
| DIN | 02564149 |
| DPD drug code | 106687 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
11 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.